Technology | Ablation Systems | May 08, 2018

Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath

Sheath helps electrophysiologists reduce dependency on fluoroscopy

Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath

May 8, 2018 — Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States. According to the company, this is the first commercially available steerable guiding sheath that can be visualized on the Carto 3 System during a catheter ablation procedure, helping electrophysiologists (EPs) reduce dependency on fluoroscopy.

A sheath is an introducer routinely used by EPs to facilitate catheter access, stability and tissue contact when targeting sites for catheter ablation to treat conditions such as atrial fibrillation. Many EPs rely on fluoroscopy to identify the location of the sheath, therefore requiring use of lead to protect themselves from radiation during the procedure. Research shows up to 62 percent of medical staff suffer chronic musculoskeletal pain from wearing these heavy protective garments.[1] Additionally, patients are exposed to a radiation dose equivalent to 830 chest X-rays during a conventional radiofrequency (RF) ablation procedure.[2]

Carto Vizigo can be visualized on the Carto 3 System map during an ablation procedure, eliminating sole dependence on fluoroscopy to determine its location. It was recently used on a patient at Massachusetts General Hospital (MGH) in Boston.

"We are always looking for ways to improve the care we deliver to our patients," said Moussa Mansour, M.D., director of the atrial fibrillation program at MGH. "One of our overall goals is to reduce dependency on fluoroscopy and gain more directional control and awareness during procedures."

Sheath visualization is incorporated easily into the EP's workflow, designed to enhance efficiency during mapping and positioning of the ablation catheter. The smooth tip-to-dilator transition promotes ease of entry into the left atrium during transseptal access, while deflections of 180 degrees in both directions mean increased steerability, which may improve access to hard-to-reach sites.

For more information: www.biosensewebster.com

 

References:

1. Goldstein JA, et al. Occupational Hazards of Interventional Cardiologists: Prevalence of Orthopedic Health Problems in Contemporary Practice Catheterization and Cardiovascular Interventions 63:407–411 (2004).

2. Effective dose of 16.6 (6.6-59.2) mSv Ref: Picano et al. Risks Related to Fluoroscopy Radiation Associated with EP Procedures. JAFIB Aug-Sep 2014.  

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init